Market sales situation and future development trend of China's hemostatic drug industry in 2018

Source: China Report Network

Chinese hemostatic drugs are drugs that can stop bleeding in and out of the body. Blood is an important substance in the human body. If it is not timely and effective to stop bleeding in case of accidental massive bleeding, it may lead to coma, shock and even life-threatening. In the course of surgery in China, the use of hemostatic drugs can also enhance the clarity of the doctor's vision, avoid important tissue damage, shorten the operation time in China, reduce postoperative drainage, shorten the time of hemostasis and reduce the incidence of infection. Therefore, the application of hemostasis in China has important clinical significance. According to the principle of clinical hemostasis, hemostatic drugs can be mainly divided into the following categories. Among them, the main product “Su Ling” belongs to hemagglutinase drugs that activate the blood coagulation process.

Hemostatic drugs can produce hemostasis by contracting arterioles and capillaries, or enhancing platelet function, or accelerating, enhancing blood coagulation, or inhibiting clot lysis. In the past decade, biochemical hemostatic drugs with hemostatic enzymes extracted from snake venom as the main component have become the most popular in clinical applications, and have become the mainstream drugs for clinical treatment of bleeding disorders or bleeding. At present, there are about 20 kinds of hemostatic drugs commonly used in clinical practice in China, which are divided into four categories according to different links acting on the coagulation mechanism. Procoagulant active drugs: Stop bleeding by affecting certain clotting factors, promoting or restoring the clotting process. Representative drugs include hemagglutinase, desmopressin, vitamin K1, vitamin K3, vitamin K4, vinegar glycine ethylenediamine.

With the continuous advancement of medical technology and the affirmation and promotion of relevant surgical techniques by government departments, especially the promotion of day surgery and minimally invasive surgery, the acceptance of patients has gradually increased, and the demand for surgery has been released in China. The market has had a positive impact. At the same time, with the continuous renewal of the concept of hemostasis, new Chinese blood drugs have also been introduced. The rapid development of bio-engineered drugs and the continuous emergence of recombinant protein products have pushed China to promote the steady growth of the global procoagulant drug market. These factors have jointly promoted the rapid growth of the hemostatic drug market in China.

The number of patients with hemostasis needs in China is about 900 million in China each year. It is mainly distributed in the surgical department of China and some internal medicine departments. Among various hemostasis methods, hemostatic drugs are widely used. In recent decades, hemostatic drugs such as hemagglutinin in China have been widely used in various operations in China because of their limitations on surgical sites and surgical procedures.

According to the statistics of the Southern Institute of Medical Economics, the market sales of China's hemostatic medicine hospitals continued to grow faster than China in recent years. The sales of hospitals in China in 2015 reached 69.33 billion yuan in China, and the compound growth of China in 2009 to China in 2015 China is 15.49% China's, and its growth is better.

From the perspective of clinical product application in China, there are currently more than 20 Chinese hemostatic drugs commonly used in China, and their coagulation mechanisms are also different:

1 activation of the coagulation process: mainly procoagulant active drugs, which affect some of the coagulation factors, promote China to enter or restore the blood coagulation process and stop bleeding.

2 reduce capillary permeability: enhance the resistance of capillaries to damage, reduce the permeability of capillaries through China, promote the contraction of damaged capillary ends and stop bleeding.

3 anti-fibrinolytic: plasminogen can not be activated by inhibiting the activator of fibrinogen, thereby inhibiting the dissolution of fibrin.

4 other topical hemostatic drugs. Among them, the largest sales volume in the hemostatic drug market is the procoagulant active drug. In recent years, the market share of procoagulant active drugs in the field of hemostatic drugs has been continuously improved, showing a good momentum of development. In 2009, the sales of China's procoagulant active drugs were about 21.08 billion yuan in China. In 2015, China grew to 57.81 billion yuan in China, and the annual growth rate in China was 18.31%. In 2015, China's annual procoagulant active drugs The hospital market share of surgery to stop bleeding is 83.39% of China, which is the main component of the market.

In China's market segment of procoagulant active drugs, the largest variety is hemagglutinase preparation, and the sales volume of hemagglutinase preparations is increasing rapidly. In the past seven years, its market share has remained at the first place. In 2009, the sales volume of China's hemagglutinin hospital market was China's 16.6 billion yuan. In 2015, China's annual growth to China's 41.75 billion yuan, the compound annual growth rate of China is 17.33%. In particular, the "biological" hemagglutinase extracted from snake venom is popular in clinical applications in China, and has become the mainstream drug for clinical treatment of bleeding disorders or bleeding.

Source: Guanyan Tianxia (YZ)